

# **Exhibit 230**

## **(Filed Under Seal)**

To: OPDP Submissions[DDMAC.Submissions@frx.com]  
Cc: Avena, Paul[Paul.Avena@frx.com]; Ottoson, Fred[Fred.Ottoson@frx.com]; Creech, Kristen[Kristen.Creech@frx.com]; D'Onofrio, Jacqueline[Jacqueline.D'Onofrio@frx.com]; Theodore, Maria[Maria.Theodore@frx.com]; Palame, Nicole[Nicole.Palame@frx.com]; Maher, Peter[Peter.Maher@frx.com]; Mastrosimone, Laura[Laura.Mastrosimone@frx.com]; Fung, Elizabeth[Elizabeth.Fung@frx.com]; Fan, Ermei[Ermei.Fan@frx.com]; Katz, Itiel[Itiel.Katz@frx.com]; Cantor, Jade[Jade.Cantor@frx.com]; Pandya, Shweta[Shweta.Pandya@frx.com]; Gerlough, Beth[Beth.Gerlough@frx.com]; Burnaska, Jeffrey[Jeffrey.Burnaska@frx.com]  
From: Burnaska, Jeffrey  
Sent: Fri 2/14/2014 7:48:37 PM  
Importance: Normal  
Subject: FINAL SAMPLES FOR OPDP SUBMISSION: Namenda XR Medscape Pharmacist Discontinuation emails  
[NXR15326\\_Medscape pharmacist Discontinuation Email.pdf](#)

**Document Name**

[NXR15326\\_Medscape pharmacist Discontinuation Email \(v0.4\)](#)

**Document Number**

[VV-15326](#)

**Product**

Namenda XR

**Owner**

Itiel Katz

**Regulatory Confirmation Requested By**

2/14/14

**Date of First Use**

2/18/14

**Project Description**

emails alerting pharmacists of the withdrawal of Namenda

HIGHLY CONFIDENTIAL  
HIGHLY CONFIDENTIAL

FRX-NY-01639069  
FRX-TX-01638736

HIGHLY CONFIDENTIAL

FRX-AT-01657074

**SAP #**

**Submission Code**

www-ecomm

**Material Classification**

Professional

**2253 Form Comments**

namenda and namenda xr

**Jeff Burnaska**

**Senior Operations Associate | Marketing Practices**

**Forest Laboratories, Inc. | 909 Third Avenue | New York, NY 10022**

**P: 646-231-7319 | Ext: 47319 | E: [Jeffrey.Burnaska@frx.com](mailto:Jeffrey.Burnaska@frx.com)**

HIGHLY CONFIDENTIAL  
HIGHLY CONFIDENTIAL

FRX-NY-01639070  
FRX-TX-01638737

HIGHLY CONFIDENTIAL

FRX-AT-01657075